State of the Art of Pathologic and Molecular Testing

Advances in the treatment of non-small cell lung carcinoma have resulted in improved histologic classification and the implementation of molecular testing for predictive biomarkers into the routine diagnostic workflow. Over the past decade, molecular testing has evolved from single-gene assays to hi...

Full description

Saved in:
Bibliographic Details
Published inHematology/oncology clinics of North America Vol. 37; no. 3; p. 463
Main Author Dacic, Sanja
Format Journal Article
LanguageEnglish
Published United States 01.06.2023
Subjects
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
High-Throughput Nucleotide Sequencing - methods
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Molecular Diagnostic Techniques
Mutation
Tumor Microenvironment
PD-L1
Molecular testing
NGS-AI
Lung cancer
Online AccessGet more information

Cover

More Information
Summary:Advances in the treatment of non-small cell lung carcinoma have resulted in improved histologic classification and the implementation of molecular testing for predictive biomarkers into the routine diagnostic workflow. Over the past decade, molecular testing has evolved from single-gene assays to high-thoroughput comprehensive next-generation sequencing. Economic barriers, suboptimal turnaround time to obtain the results, and limited tissue available for molecular assays resulted in adoption of liquid biopsies (ctDNA) into clinical practice. Multiplex immunohistochemical/immunofluorescence assays evaluating tumor microenvironment together with the AI approaches are anticipated to translate from research into clinical care.
ISSN:1558-1977
DOI:10.1016/j.hoc.2023.02.001